JPH1033584A - Lacrimal duct insertion appliance - Google Patents

Lacrimal duct insertion appliance

Info

Publication number
JPH1033584A
JPH1033584A JP8214093A JP21409396A JPH1033584A JP H1033584 A JPH1033584 A JP H1033584A JP 8214093 A JP8214093 A JP 8214093A JP 21409396 A JP21409396 A JP 21409396A JP H1033584 A JPH1033584 A JP H1033584A
Authority
JP
Japan
Prior art keywords
member
lacrimal
end
central member
central
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP8214093A
Other languages
Japanese (ja)
Inventor
Katsuaki Kurihashi
栗橋克昭
Original Assignee
M L C:Kk
有限会社エム・エル・シー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M L C:Kk, 有限会社エム・エル・シー filed Critical M L C:Kk
Priority to JP8214093A priority Critical patent/JPH1033584A/en
Publication of JPH1033584A publication Critical patent/JPH1033584A/en
Application status is Granted legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00772Apparatus for restoration of tear ducts

Abstract

PROBLEM TO BE SOLVED: To provide a lacrimal insertion appliance used for rebuilding of the lacrimal ducts, as a replacement of a lacrimal punctum plug or as a drug delivery system for treatment of the glaucoma, uveites, conjunctivitis, keratitis and general diseases having good stability in the lacrimal ducts, having easy insertion into the lacrimal ducts and having no possibility of generating laceration in the lacrimal punctum and the lacrimal canaliculus after indwelling. SOLUTION: This appliance comprises one central member 50 arranged between two end members 51 and two end members 51 and two connecting members 71 connecting the two end members 51 and the central member 50. The appliance has two notches 5 for insertion of a bougie 91 and the end members 51 are formed of pipe materials. The terminals thereof are formed as blind ends 53 reinforced by reinforcing materials, such as stainless steels. The connecting members 71 are more pliable than the end members 51 and the central member 50 and the outside diameter of the connecting member 71 is formed smaller than the outside diameter of the end members 51 and the central member 50. The utilization of the appliance as a drug delivery system is made possible by including drugs into the central member 50 and the end member 51 and mounting a drug releasing device 25 at the center of the central member 50.

Description

【発明の詳細な説明】 DETAILED DESCRIPTION OF THE INVENTION

【0001】 [0001]

【産業上の利用分野】この発明は、涙道閉塞や涙道の炎症や結膜炎や角膜炎やぶどう膜炎やドライアイや緑内障の治療のための涙道内挿管器具に関する。 BACKGROUND OF THE INVENTION This invention relates to a lacrimal duct intubation instrument for the treatment of lacrimal duct obstruction or lacrimal irritation and conjunctivitis and keratitis and uveitis and dry eye and glaucoma.

【0002】 [0002]

【従来の技術】図1に示すように、涙液は涙腺19から分泌され、涙道を通って下鼻道に排出される。 As shown in Prior Art FIG. 1, lacrimal fluid is secreted from the lacrimal gland 19 and is discharged to the lower meatus through the lacrimal canal. 涙道は、 Tears tract,
上涙点11、下涙点12、上涙小管13、下涙小管1 Upper punctum 11, lower punctum 12, the upper canaliculus 13, the lower canaliculus 1
4、総涙小管15、涙嚢16、鼻涙管17からなり、鼻涙管17の下端は下鼻道に開いている。 4, the total canaliculus 15, lacrimal sac 16, consists of nasolacrimal duct 17, the lower end of the nasolacrimal duct 17 is open to the lower nasal passages. 緑内障の治療に用いられているピロカルピンなどの点眼薬は、涙道を通ってすぐに排出されてしまうのが問題となっており、この排出を抑えるために、点眼後数分間、上涙点11、下涙点12を指で圧迫することも行われている。 Ophthalmic drugs such as pilocarpine, which is used in the treatment of glaucoma, are from being discharged immediately through the lacrimal duct becomes a problem, in order to reduce the discharge, eye drops after a few minutes, upper punctum 11 , has been carried out is also possible to compress the lower punctum 12 with a finger.

【0003】点眼されたピロカルピンなどの薬物はまず涙液と混合されるが、この時点で、角膜と眼瞼の間のスペースを超過した薬液は、眼外に涙と共に流れ去る。 [0003] drugs such as eye drops have been pilocarpine but is first mixed with tear fluid, at this point, the chemical liquid exceeds the space between the cornea and eyelid, flows away along with tears outside the eye. また超過した薬液の一部は、涙道を通り、鼻腔へ向けて流れ去る。 Also part of the excess chemical solution, through the lacrimal duct, flow away toward the nasal cavity.

【0004】眼に残留した薬物は涙液で希釈され、指数関数的に薬物は消失してゆき、その半減期は3〜8分と報告されている。 [0004] Drug remaining in the eye is diluted with lacrimal fluid, exponentially drug Yuki disappeared, its half-life is reported to be 3-8 minutes. たとえば Mishima et a For example, Mishima et a
l:Determination of tear v l: Determination of tear v
olume and tear flow. olume and tear flow. Inve Inve
st Ophthalmol 5:264,1966. st Ophthalmol 5: 264,1966.
を参照。 See. さらに点眼された薬物は、角膜を通して角膜と水晶体の間のスペースにある眼房水に流入するが、その量は極めて少ない。 Further ophthalmic drug is flowing into the aqueous humor in the space between the cornea and crystalline lens through the cornea, the amount is very small. 緑内障は角膜と水晶体間を占める眼房水の慢性的な流出入異常が原因である。 Glaucoma is a chronic inflow and outflow abnormality is the cause of the aqueous humor, which accounts for between cornea and crystalline lens. そのため治療薬は角膜を通過して持続的に眼房水に流入するのが望ましい。 Therefore the therapeutic agent is desirable to flow into the continuously aqueous humor through the cornea. たとえば川口健夫、他『眼粘膜投与剤形とそのメカニズム』薬局39:1287,1988. For example Takeo Kawaguchi, et al., "Eye mucosal dosage form and its mechanism" Pharmacy 39: 1287,1988. を参照。 See.

【0005】点眼投与は、決して理想的な薬物投与方法とはいえない。 [0005] ophthalmic administration, it can not be said that never ideal drug administration method. とくに、点眼した薬物が眼内に移行し、 In particular, ophthalmic drug migrates into the eye,
所期の治療効果を発揮することを目的とする場合、点眼された薬物のうち、眼内にはわずかに数パーセントが移行するにすぎないこと、さらに眼内に移行した薬物濃度は15〜60分後に最高値に達した後、時間とともに指数関数的に減少する。 If it is intended to exert the desired therapeutic effect, of the ophthalmic drug, it only slightly shifts a few percent in the eye, the drug concentration was further shifted to the eye 15-60 after reaching the maximum value after the minute, it decreases exponentially with time. 奏効器(effector si Response device (effector si
te)の薬物濃度がある程度以下に低下すると、薬物の治療効果が失われる。 When drug concentrations te) drops below a certain degree, it is lost the therapeutic effect of the drug. 点眼された薬物の眼内移行量は、 Ocular amount of ophthalmic drug is
一般に投与量に依存する。 In general dose dependent. 点眼により投与した薬物の治療効果をある程度持続させるためには、効果を得るのに必要最小量をはるかに越えた多量を一度に投与すること(overdosing)が必要である。 To some extent sustain the therapeutic effect of a drug administered by instillation, it (overdosing) is required to be administered at once far beyond the large amount of the necessary minimum amount to achieve the effect. さらに、眼内薬物濃度が治療効果を発揮するには、不十分なレベルに低下した少量投与状態(underdosing)で再び多量の薬物投与(overdosing)を行うのが、現在われわれが行っている点眼療法である。 Moreover, instillation therapy intraocular drug concentration exert a therapeutic effect, to perform a large amount of the drug administered again in a small amount administered a degraded state to insufficient levels (underdosing) (overdosing), we now have done it is. 点眼療法は、必要量をはるかに越えた薬物投与を行っていることから、不経済であるのみならず、薬剤の局所的ならびに全身的副作用の発生の危険性が大きいこと、少量投与(underdosing)の期間は、十分な治療効果が得られないこと、患者自身が点眼を行うことから、患者の自発的な協力(compliance)に依存するところが大きいこと、などの短所をもっている。 Eye therapy, since it is performed much drug administration exceeding the required amount, not only is uneconomical, it is larger local and risk of the occurrence of systemic side effects of drugs, small amounts administered (underdosing) the period of time sufficient to therapeutic effects can not be obtained, since the patient's own perform instillation, have it largely depends on the voluntary cooperation of the patient (compliance), the disadvantages such as. たとえば北澤克明『Ocusertの効果と使用法』眼科2 For example, Katsuaki Kitazawa "effect and use of the Ocusert" ophthalmology 2
6:925−928,1984. 6: 925-928,1984. を参照。 See.

【0006】たとえば塩酸ピロカルピンの点眼剤は眼圧降下作用があるため、緑内障治療薬として古くから用いられているが、実際に実施可能な6時間ごとの点眼が一般に行われている。 [0006] For example for eye drops pilocarpine hydrochloride have a working ocular hypotensive, have been used since ancient times as a glaucoma therapeutic agent, actually feasible 6 hourly instillation is generally performed. この方法では眼前房内ピロカルピン濃度の振幅はきわめて大きい。 Amplitude before eyes intracameral pilocarpine concentration in this way is very large. これはある程度の効果持続時間をもたせるためには多量投与(overdosi This is a large amount of administration in order to have a certain degree of effect duration (overdosi
ng)がやむを得ないことに基づく。 ng) based on it is unavoidable. 多量投与(ove High-dose (ove
rdosing)はピロカルピンの眼圧降下作用を増強させるが、同時に副作用も増強させる。 rdosing) is to enhance the intraocular pressure reducing effect of pilocarpine, side effects also enhance at the same time. ピロカルピンの副作用としては、近視化、縮瞳による暗黒感がある。 Side effects of pilocarpine, there is a dark sense of myopia reduction, due to miosis. 毛様体筋を収縮させるため近視となり、遠方が見えにくくなる。 Become a myopic order to contract the ciliary muscle, the distance becomes difficult to see. 若年者では眼鏡補正の必要なこともある。 It may be required of glasses correction in young people. また、 Also,
縮瞳をおこすため、患者は暗黒感を訴えるようになり、 In order to cause miosis, the patient is now complain of dark feeling,
夜間の車の運転が困難となる。 Operation of the night of the car becomes difficult. また白内障患者ではとくに視力低下が強められる。 The particular vision loss in cataract patients is strengthened. さらに、点眼したものが涙道を経て鼻腔へ排出され、粘膜から吸収されるが、これによって発汗、唾液分泌増加、嘔吐、下痢などの全身的副作用があげられる。 In addition, what was instilled is discharged through the road tears to the nasal cavity, but is absorbed from the mucous membrane, this by sweating, salivation increase, vomiting, systemic side effects such as diarrhea, and the like. たとえば新家 真『オキサート眼科用治療システム』日本臨床47:1357−1362, For example, new house true "Okisato ophthalmic treatment system" Japan clinical 47: 1357-1362,
1989. 1989. を参照。 See.

【0007】以上のように、治療効果を持続させるためには有効量以上の頻回の点眼が必要であり、持続的な望ましい眼圧を維持することが困難であった。 [0007] As described above, in order to prolong the therapeutic effect is required ophthalmic effective amount more frequent, it is difficult to maintain a sustained desired intraocular pressure. ピロカルピンの副作用を軽減するために考えられたのが図2に示すオキュサート(Ocusert)25である。 Was thought to reduce the side effects of pilocarpine is Okyusato (Ocusert) 25 shown in FIG. オキュサート25は米国のALZA社により開発された薬物投与システムで、米国では1974年より、日本では198 Okyusato 25 is a drug administration system which has been developed by the United States of ALZA Corporation, in the United States since 1974, in Japan 198
1年より(藤沢薬品から)市場提供されている。 Than a year has been provided (Fujisawa from chemicals) market. 図2に示されるように、オキュサート25は楕円形の高分子膜21と辺縁部の白色の支持体24と薬物貯蔵部22からなる。 As shown in FIG. 2, Okyusato 25 consists of white support 24 and the drug reservoir 22 of the polymer film 21 and the edges of the oval. 高分子膜21と白色の支持体24はエチレンビニルアセテート共重合体でできている。 Polymer film 21 and the white support 24 is made of ethylene vinyl acetate copolymer. 薬物貯蔵部22はピロカルピンコア22で、これは塩酸ピロカルピンとアルギン酸を囲んだ製剤である。 Drug reservoir 22 is pilocarpine core 22, which is a preparation enclosed pilocarpine hydrochloride and alginic acid. 高分子膜21は薬物放出調節膜21として働き、結膜に1回挿入するだけで、1 Only polymer membrane 21 acts as a drug release controlling membrane 21 is inserted once into the conjunctiva, 1
週間にわたって涙液中に少しずつピロカルピンを放出する。 Release pilocarpine little by little in tears over the week. エチレンビニルアセテート共重合体は化学的にはポリエチレンに類似し、透明な柔軟性膜を構成し、物質に対して選択的な透過性を有する。 Ethylene-vinyl acetate copolymer is chemically similar to polyethylene, constitute a transparent flexible membrane, having selective permeability to substances. 酸化チタン(Ti Titanium oxide (Ti
2 )は白色顔料で支持体24にしみ込まされている。 O 2) is impregnated in the support 24 with white pigment.
先述のアルギン酸は海草より分離された粘性物質で、ピロカルピンの担体として使われている。 Foregoing alginate is a viscous material separated from the seaweed, it has been used as carriers of pilocarpine. オキュサート2 Okyusato 2
5にはP−20とP−40の2種類がある。 The 5 there are two types of P-20 and P-40. オキュサートP−20は1週間にわたり涙液中に1時間につき20 The Okyusato P-20 20 per hour to tear fluid over a period of 1 week
μgの割合で、P−40は1時間につき40μgの割合で塩酸ピロカルピンを放出する。 At a rate of [mu] g, releasing pilocarpine hydrochloride in a ratio of P-40 is 40μg per hour. オキュサートP−40 Okyusato P-40
の膜21にはピロカルピンのエチレンビニルアセテート共重合体膜21よりの放出性を高めるためにジ(2−エチルヘキシル)フタレート(2)2mgが加えられている。 The membrane 21 is di (2-ethylhexyl) phthalate (2) 2 mg was added in order to increase the release of more ethylene-vinyl acetate copolymer film 21 of pilocarpine. たとえば鈴木徳治『製剤の進歩による新しい薬剤』 For example, Tokuji Suzuki "new drug by the progress of the preparation"
内科49:696−701,1982. Internal Medicine 49: 696-701,1982. 参照。 reference.

【0008】オキュサート25は従来の点眼剤に比べ、 [0008] Okyusato 25 compared to conventional eye drops,
挿入が週1回でよいので、1日に数回の点眼の煩わしさが避けられる。 The insertion may be once a week, the hassle of the few times of eye drops a day is avoided. これによれば就寝時の眼圧コントロールが可能である。 It is possible intraocular pressure control bedtime According thereto. オキュサート25は眼内薬物量を一定に保つことが不可能な点眼剤と異なり、一定の有効薬物量を維持し、安定した眼圧調節効果を示す。 Okyusato 25, unlike ophthalmic solution can not be maintained constant intraocular drug amount, to maintain a constant effective amount of drug, showing a stable intraocular pressure regulating effect. それにより、 Thereby,
塩酸ピロカルピンの投与による縮瞳などの副作用を避けられる。 Avoid side effects such as miosis by the administration of pilocarpine hydrochloride. 薬物の総投与量は点眼剤に比べてはるかに少ない。 The total dose of the drug is much smaller than the eye drops. このような利点を有しているが、しかし、オキュサートは後述の諸問題があり、普及するに至らず、わが国においては1994年3月頃からほとんど使用されなくなっている。 But has such advantages, however, Okyusato has problems described below, not enough to spread, in our country are no longer little used from around March 1994.

【0009】ドライアイは涙腺19から分泌される涙液量が少ないために起こる病気で、涙液が涙道に排出されてゆくのを防止するために、上涙点11、下涙点12を焼灼して塞いだり、涙点プラグで塞いだりすることが行われている。 [0009] Dry eye is a disease that occurs due to the small amount of tears that is secreted from the lacrimal gland 19, in order to tear can be prevented from Yuku is discharged into the canal tears, upper punctum 11, the lower punctum 12 clogged with ablation, it has been done to clogged with tears point plug. また涙道内にシリコーンチューブを留置する方法は、涙道閉塞の治療のために有効な治療法である。 The method of placing a silicone tube to the lacrimal duct is an effective therapy for the treatment of lacrimal duct obstruction. しかし、クロフォード法に代表される従来のシリコーンチューブ留置法においては、その挿入方法が難しく、留置されたシリコーンチューブに十分な安定性がないため、一般には普及していない。 However, black in the conventional silicone tube indwelling method typified Ford method, it is difficult to its insertion method, since there is no sufficient stability indwelling silicone tube, generally not popular. 従来のシリコーンチューブはチューブの中央部の柔軟性が不十分であった。 Conventional silicone tube was insufficient flexibility in the center portion of the tube.
したがって、その中央部をピンセットで持ち上げても逆U字型に強く折れ曲がることがなかった。 Therefore, it never bent strongly its central portion is also lifted with forceps in an inverted U-shape. このチューブの中央部分の弾力性が涙道内の不安定性の一因となっていた。 Elasticity of the central portion of the tube has been a cause of instability of the lacrimal duct. またクロフォード法ではチューブの先端を鼻腔内で結び、鼻涙管下端の開口部の大きさより大きな結び目をつくり、そのまま放置する構成になっていた。 The bear distal end of the tube in the nasal cavity in Crawford method, make a greater knot than the size of the opening of the nasolacrimal duct lower end and has composition stay standing. しかし、鼻涙管下端の開口部の大きさを確認することは困難である。 However, it is difficult to confirm the size of the opening of the nasolacrimal duct bottom. また結び目が鼻涙管下端の開口部より小さいときは、結び目が上方に移動して涙嚢内に入ってしまう難点もあった。 Also, when the knot is less than the opening of the nasolacrimal duct lower end, the knot was also difficulty accidentally get tears sac moves upward. 涙小管の径が非常に小さいため、一度涙嚢に入った結び目を抜去することは非常に困難であった。 Since the diameter of the canaliculus is very small, it is very difficult to removed the knot entering once lacrimal sac.

【0010】そこで、本発明者は、全長が80〜130 [0010] It is an object of the present invention have an overall length of 80 to 130
mmであり、中央部の20〜40mmの部分が細くしなやかになったチューブを発明した。 A mm, invented the tube is part of 20~40mm the central portion becomes thin and supple. このチューブは中央部が細くかつしなやかで、その両端が太く硬めになっていて、中央部を持ち上げると重力で楽に逆U字型に湾曲する構成になっている。 The tube is and thinner central portion supple, and both ends have become thicker stiffer, has to lift the structure for easily curved in an inverted U-shape by gravity a central portion. したがって、このチューブは従来のシリコーンチューブと比較して安定性が格段に優れていて抜け出しが起こることは非常にまれである。 Therefore, the tube is to exit though stability is remarkably superior to the conventional silicone tube occurs is very rare. また、このチューブは両端が盲端となっていて、消息子を挿入する切れ目を有するので、涙道内への挿入も容易である。 Further, the tube ends have a blind end, because it has a cut for inserting the anti sons, inserted into the lacrimal duct is easy. さらに抜去も容易にできる等の利点も有している。 Also has advantages such as further removal can be facilitated. 本発明者はこのチューブを100例以上の涙道閉塞の症例に適用したが、涙道内での安定性がよく、抜け出しがまれであることが確認されている。 The present inventor has been applied to the tube to cases 100 cases over lacrimal duct obstruction, good stability in the lacrimal duct, exit is has been confirmed that it is rare. また、このチューブはドライアイや緑内障の治療の一助として、涙道を塞いだり狭くしたりするためにも有用であることを確認している。 In addition, the tube has been confirmed that as an aid in the treatment of dry eye and glaucoma, which is also useful for or to narrow or block the lacrimal passage. また従来の涙点プラグにおいては、その安定性が悪いため抜け出したりすることが多く、涙点プラグの先端の刺激で涙小管閉塞を起こすことが多かったが、 In the conventional punctal plugs, the often stability or escape due to poor, but it was often cause canaliculus blockage at the tip of the stimulation of the punctal plug,
涙点プラグの代わりにこのチューブを用いると、抜け出したり涙小管閉塞を起こしたりすることはまれである。 Using this tube instead of punctal plugs, it is rare to or causing canaliculus blockage or exit.

【0011】 [0011]

【発明が解決しようとする課題】しかしながら、一般にチューブの両端は涙道の働きによって鼻腔の方に引っ張られる。 [SUMMARY OF THE INVENTION However, both ends of the generally tube is pulled towards the nasal cavity by the action of lacrimal duct. このため図3に示すように、チューブ中央部の細くしなやかな部分40が涙点や涙小管に食い込んで、 Therefore, as shown in FIG. 3, thin flexible portion 40 of the tube central portion bites into the lacrimal punctum and canaliculus,
涙点や涙小管に裂傷41が生じる場合があった。 There have been cases where laceration 41 occurs in tears point and canaliculus. 裂傷は涙点に触れるチューブの中央部が細く硬いほど生じ易い。 Laceration is likely to occur as hard narrow central portion of the tube touching the tears point. チューブ中央部が比較的太くても、その材質が軟らかすぎる場合には、チューブ中央部は引っ張られ、細く硬くなってしまうため、裂傷41が生じ易い。 It is the center of a tube is relatively thick, if the material is too soft, the tube center portion is pulled, since it becomes thinner hard, easy tear 41 occurs. またチューブの中央部を形成する材質が軟らかすぎる場合には、 Further, when the material forming the central portion of the tube is too soft, the
その中央部をピンセットでつまんで持ち上げたとき、チューブが強い逆U字型になるが、そのようなチューブを使用すると裂傷41が生じやすい。 When lifted by pinching the center portion with tweezers, tube but is strong inverse U-shape, tear 41 is likely to occur when using such tubes. また、図4に示すように、チューブ挿入時に、チューブの先端部の壁42が消息子91の先端93で突き破られることがまれでなく、このようなことはチューブの壁をつくる材質の硬度が小さいほど、またその肉厚が薄いほど起こりやすい。 Further, as shown in FIG. 4, during tube insertion, the wall 42 of the distal portion of the tube is not uncommon to be pierced by the tip 93 of the extinguishing son 91, materials such things make the walls of the tube hardness the smaller, also likely to occur as the thickness of the thin.
また涙道にチューブを留置すると感染が起こりやすくなる。 Also likely to occur infection and placing a tube in the road tears.

【0012】図2に示すオキュサート25はコンタクトレンズのように眼に入れて使用するが、オキュサート2 [0012] Okyusato 25 shown in FIG. 2 are used to put the eye as contact lenses, but Okyusato 2
5による眼表面に対する刺激で患者は異物感、充血、流涙、眼脂、眼痛を訴えることや、オキュサート25の挿入や除去に際しては取り扱いが難しいことや、オキュサート25が頻回に脱落したり紛失したりすることや、患者がオキュサート25の脱落に気づかずにいることがあるため、投薬されない状態が続くことや、オキュサート25が脱落していないのに脱落したと思い、2個挿入してしまうことがあることが問題となっている。 5 patients with foreign body sensation in the irritation to the eye surface by, hyperemia, tearing, eye discharge, and to sue the eye pain, it is difficult to handle and is upon insertion and removal of Okyusato 25, or drop off Okyusato 25 frequent lost or that or, because there is that the patient is not aware of the dropping of the Okyusato 25, it and the state that are not dosed continues, I think Okyusato 25 dropped out to not fall off, two insert and that there be put away has become a problem. たとえば中島 章『時効型眼科用剤』臨床と薬物治療8:516 For example, Akira Nakajima "aging type ophthalmic agent" clinical and drug treatment 8: 516
−519,1989. -519,1989. を参照。 See. 以上のオキュサート25 More Okyusato 25
のかかえている問題は、いずれもオキュサート25が眼表面において固定されておらず、コンタクトレンズのように動きやすいということに基づいている。 Problem suffer of both Okyusato 25 is not fixed in the eye surface, it is based on the fact that easy to move as contact lenses.

【0013】このような従来技術の問題点に鑑み、本発明は涙道内での安定性が良く、涙道内への挿入が容易であって、留置後に涙点や涙小管に裂傷や感染が生じる恐れがなく、消息子でチューブが破れる恐れがないようにすることを目的としている。 [0013] In view of such problems of the prior art, the present invention has good stability in the lacrimal duct, it is easy to insert into the lacrimal duct, tears and infection occur in the punctum or canaliculus after indwelling there is no fear, it is an object to ensure that there is no risk of broken tube in consumption son.

【0014】本発明の別の目的は、涙道閉塞や涙道の炎症やドライアイや緑内障の治療のためのドラグデリバリーシステムとしても利用できる涙道内挿管器具を提供することである。 Another object of the present invention is to provide a lacrimal duct intubation instrument can also be used as a drag delivery system for the treatment of inflammation and dry eye and glaucoma lacrimal duct obstruction or lacrimal canal.

【0015】 [0015]

【課題を解決するための手段】本発明は、前述の2つの目的の少くとも一方を達成するために、請求項1〜24 The present invention SUMMARY OF], in order to achieve one at least of the two purposes described above, according to claim 1 to 24
のいずれか1項に記載の涙道挿管器具を要旨としている。 It is summarized as lacrimal intubation device according to any one of.

【0016】たとえば、本発明の器具は左右対称形の2 [0016] For example, the instrument of the present invention is a symmetrical type 2
つの端部材51と、それら2つの端部材51の間に配置される1つの中央部材50と、2つの端部材51の各々を中央部材50に連結する2つの連結部材71から構成されている。 One of the end member 51, which one of the central member 50 disposed between the two end members 51, are configured to each of the two end members 51 of two connecting members 71 for connecting the central member 50. 各端部材51は、消息子91を挿入するための2つの切れ込み55を有している。 Each end member 51 has two notches 55 for insertion of the extinguishing son 91. 端部材51はパイプ材で形成され、その終端が盲端53になっている。 End member 51 is formed of a pipe material, its end is in blind end 53.
連結部材71は端部材51や中央部材よりしなやかで、 Connecting member 71 is pliable than the end members 51 and central member,
連結部材71の外径は端部材51や中央部材50の外径よりも小さくなっている。 The outer diameter of the connecting member 71 is smaller than the outer diameter of the end member 51 and central member 50. そして、中央部材50に薬物放出装置25を装着したり、中央部材50や端部材51 Then, or wearing the drug release device 25 to the central member 50, central member 50 and end member 51
に薬物を含ませたりして、涙道閉塞の治療のためのステントとしてばかりでなくドラグデリバリーシステムとしても利用でき、さらにドライアイの治療のための涙点プラグの代わりに使用できる。 With or impregnated with a drug, can also be used as a drag delivery system as well as a stent for the treatment of lacrimal duct obstruction, it can be further used in place of the punctal plug for the treatment of dry eye.

【0017】 [0017]

【実施例】以下、図面を参照して、本発明の涙道挿管器具の実施例を説明する。 EXAMPLES Hereinafter, with reference to the drawings, an embodiment of a lacrimal intubation device of the present invention.

【0018】図5と図6と図7は、本発明による涙道挿管器具(以下、単に挿管器具という)を示しており、図5と図6は断面図、図7はその外形を示す斜視図である。 [0018] Figures 5 and 6 and 7, lacrimal duct intubation instrument according to the invention (hereinafter, simply referred to as intubation device) indicates the Figures 5 and 6 is a sectional view, FIG. 7 is a perspective showing the outline it is a diagram. 挿管器具は両側に配置される2つの端部材51と2 Intubation device and the two end members 51 disposed on both sides 2
つの端部材の間にある1つの中央部材50と端部材51 One central member 50 which is between the One end member and the end member 51
と中央部材50を連結する2つの連結部材71から構成されている。 It is composed of two connecting members 71 for connecting the central member 50 and. 中央部材50と連結部材71はシリコーンゴム製で、この実施例では端部材51もシリコーンゴムから成っている。 Central member 50 and the connecting member 71 is made of silicone rubber, in this embodiment consists also silicone rubber end member 51. 端部材51の終端部53(1mm)は盲端になっている。 Terminal end 53 of the end member 51 (1 mm) is in a blind end. また端部材51の中央寄りの端の部分には、消息子91を挿入するための小さな切れ込み5 Also in the inboard end portion of the end member 51, a small incision 5 for inserting a vanishing son 91
5が形成されている。 5 is formed. 切れ込み55は軸芯方向に平行に形成されている。 Notch 55 is formed parallel to the axial direction. 消息子91を切れ込み55から盲端まで挿入して、消息子91を利用して挿管器具を涙道内に留置するのである。 The extinguishing son 91 is inserted from the notch 55 to the blind end, it is to deploy the intubation device to the lacrimal duct by using an anti-son 91. この実施例では、連結部材71の外径は端部材51や中央部材50の外径より小さくしなやかで、図5に示すように中実のロッド、または図6に示すようにパイプ状になっている。 In this embodiment, the outer diameter of the connecting member 71 is pliable smaller than the outer diameter of the end member 51 and central member 50, is in a pipe shape as shown in the solid rod or 6, as shown in FIG. 5 there. さて挿管器具の材料としては、しなやかさと強度が必要とされる。 Now as the material of the intubation device, suppleness and strength is required. 強度的には涙道内への留置操作で加わる引っ張り力、留置後に働く引っ張り力、抜去の際の引っ張り力等に耐え得る強度が必要である。 Strength to applied tensile force indwelling operation to lacrimal duct is tensile force acting after placement, it is necessary tensile force or the like capable of withstanding strength when the removal. 一方、しなやかさの点では、留置操作が円滑に行え、留置後の涙道内での安定性が得られるだけのしなやかさが必要である。 Meanwhile, in terms of suppleness, indwelling operations proceed smoothly, it is necessary to supple enough stability in the lacrimal duct after placement is obtained. このような引張強度としなやかさの条件に加えて、人体に無害であることも重要である。 In addition to the conditions for such tensile strength and flexibility, it is also important is harmless to the human body. このような観点から、挿管器具に適する材料として引っ張り強さ等の強度も増大する傾向にある。 From this point of view, the strength of the tensile strength or the like as a material suitable for intubation device tends to increase. 連結部材71と端部材51と中央部材50のしなやかさは、例えばJISで定められたショア硬さで評価できる。 Flexibility of the connecting member 71 and the end member 51 and central member 50 can be evaluated, for example, a Shore hardness defined in JIS. ショア硬さは硬度計デュロメーター(Durometer)で計測され、単位はshore A(JIS)である。 Shore hardness is measured in hardness tester durometer (Durometer), the unit is shore A (JIS). ショア硬さの数値が大きいほど硬さもより一層硬くなる。 Hardness higher the number of Shore hardness is greater becomes even more hard.

【0019】連結部材71と端部材51と中央部材50 The connecting member 71 and the end member 51 and central member 50
の硬さ(しなやかさ)について述べる。 It describes the hardness of (flexibility). 連結部材71はショア硬さが20〜80(shore A(JIS)) Connecting member 71 Shore hardness 20~80 (shore A (JIS))
であるが、望ましくは40〜80(shore A)、 Although, preferably 40 to 80 (shore A),
最適には50〜60(shore A)の範囲に設定できる。 Optimally it is set in the range of 50~60 (shore A). 端部材51のショア硬さが60〜80(shor Shore hardness of the end member 51 is 60-80 (shor
e A)であるが、望ましくは70〜80(shore Is a e A), preferably 70 to 80 (shore
A)、最適には75〜80(shore A)の範囲に設定できる。 A), and most can be set in the range of 75~80 (shore A). 涙道再建用として用いるときは、中央部材50はショア硬さが20〜80(shore A)であるが、望ましくは50〜80(shore A)、最適には60〜75(shore A)の範囲に設定できる。 When used as a road reconstruction tears, although the central member 50 Shore hardness is 20 to 80 (shore A), preferably 50 to 80 (shore A), the optimal range of 60 to 75 (shore A) It can be set to. 一方、中央部材50に薬物を含ませ緑内障治療用のドラグデリバリーシステムとして用いるときは中央部材50は軟らかい方がよいため、ショア硬さが20〜50 On the other hand, it is better softer the central member 50 when used as drag delivery system for glaucoma treatment contained the drug to the central member 50, a Shore hardness of 20 to 50
(shore A)であるが、望ましくは30〜50 It is a (shore A), preferably from 30 to 50
(shore A)、最適には35〜40(shore (Shore A), optimally 35~40 (shore
A)の範囲に設定できる。 It can be set in the range of A).

【0020】次に、挿管器具及び各部材の長さについて述べる。 Next, we described the length of intubation device and the member. 挿管器具の全長は一般に50〜130mmであるが、望ましくは90〜120mm、最適には95〜1 Although the total length of intubation device is generally 50~130Mm, preferably 90~120Mm, optimally from 95 to 1
10mmの範囲に設定できる。 It can be set in the range of 10mm. また、端部材51の長さは10〜60mmであるが、望ましくは30〜45m Further, the length of the end member 51 is 10 to 60 mm, preferably 30~45m
m、最適には33〜40mmの範囲に設定できる。 m, and most can be set in the range of 33~40Mm. また中央部材50の長さは15〜35mmであるが、望ましくは20〜30mm、最適には23〜28mmの範囲に設定できる。 Although the length of the central member 50 is 15 to 35 mm, preferably 20 to 30 mm, and most can be set in the range of 23~28Mm. また連結部材71の長さは2〜10mmであるが、図5に示すように連結部材71の外径は端部材51や中央部材50の内径(b)と同じ大きさで、連結部材71の両端60の各々を端部材51や中央部材50 Although the length of the connecting member 71 is 2 to 10 mm, the outer diameter of the connecting member 71 as shown in FIG. 5 is the same size as the internal diameter (b) of the end member 51 and central member 50, the connecting member 71 end members 51 each of opposite ends 60 and central member 50
に挿入し、シリコーン糊で接着する。 It is inserted into and bonded with silicone glue. 連結部材51の接着部分61、62(h、f)の長さは1〜10mmで、 The length of the bonded portion 61, 62 of the connecting member 51 (h, f) is 1 to 10 mm,
望ましくは1〜5mm、最適には1〜3mmである。 Preferably 1 to 5 mm, and optimally 1 to 3 mm. この場合、連結部材71の外面に現れている部分(g)の長さは0.5〜3mmであるが、望ましくは0.5〜 In this case, the length of the portion (g) appearing on the outer surface of the connecting member 71 is a 0.5 to 3 mm, preferably 0.5 to
1.5mm、最適には0.7〜1.0mmの範囲に設定できる。 1.5mm, and most can be set in the range of 0.7~1.0mm.

【0021】次に、各部材の外径、内径、肉厚について述べる。 Next, we described the outer diameter of the member, the inner diameter, the wall thickness. 端部材51の外径(a)、内径(b)、肉厚(c、y)は各々、0.6〜1.2mm、0.3〜0. Outer diameter of the end member 51 (a), the inside diameter (b), the thickness (c, y) each, 0.6~1.2mm, 0.3~0.
6mm、0.2〜0.5mmであるが、望ましくは各々、0.9〜1.1mm、0.4〜0.5mm、0.2 6 mm, is a 0.2 to 0.5 mm, respectively Desirably, 0.9~1.1mm, 0.4~0.5mm, 0.2
5〜0.4mm、最適には各々0.95〜1.0mm、 5~0.4mm, the best each in 0.95~1.0mm,
0.4〜0.48mm、0.25〜0.3mmの範囲に設定できる。 0.4~0.48mm, it can be set in the range of 0.25~0.3mm. 一方、中央部材50の外径(s)、内径(t)、肉厚(u)は、0.6〜1.5mm、0.3〜 On the other hand, the outer diameter of the central member 50 (s), an inside diameter (t), the thickness (u) is, 0.6 to 1.5 mm, 0.3 to
0.6mm、0.2〜0.8mmであるが、望ましくは各々、0.9〜1.3mm、0.4〜0.5mm、0. 0.6 mm, is a 0.2 to 0.8 mm, respectively Desirably, 0.9~1.3mm, 0.4~0.5mm, 0.
25〜0.5mm、最適には各々0.95〜1.0m 25~0.5mm, the best each to 0.95~1.0m
m、0.4〜0.48mm、0.25〜0.3mmの範囲に設定できる。 m, can be set 0.4~0.48mm, in the range of 0.25~0.3mm. また連結部材71の外径は端部材51 The outer diameter of the connecting member 71 is an end member 51
や中央部材50の内径(b、t)と同じで、0.3〜 The same as the inner diameter of and a central member 50 (b, t), 0.3~
0.6mmであるが、望ましくは0.4〜0.5mm、 It is a 0.6 mm, preferably 0.4 to 0.5 mm,
最適には0.4〜0.45mmの範囲に設定できる。 And most can be set in the range of 0.4~0.45mm.

【0022】図5に示す盲端部53の先端の長さ(e) The tip length of the blind end 53 shown in FIG. 5 (e)
は0.2〜2mm、望ましくは0.3〜1.5mm、最適には0.4〜0.7mmである。 It is 0.2 to 2 mm, preferably 0.3 to 1.5 mm, optimally 0.4-0.7 mm. また盲端部53の内腔の長さ(d)は0.2〜1.5mm、望ましくは0. The length of the lumen of Mekuratan section 53 (d) is 0.2 to 1.5 mm, preferably 0.
3〜1.0mm、最適には0.4〜0.7mmの範囲に設定できる。 3~1.0mm, and most can be set in the range of 0.4~0.7mm.

【0023】図8は図5、6と同じ外形であるが、中央部材50と端部材51と連結部材71が接着部分のない一体構造のものである。 [0023] Although FIG. 8 is the same contour as in FIG. 5 and 6, connected to the central member 50 and the end member 51 member 71 is of unitary construction without the adhered portion.

【0024】図9の実施例は、中央部材50、端部材5 The embodiment of FIG. 9, the central member 50, the end member 5
1、連結部材71が一体構造になっており、中央部材5 1, the connecting member 71 has become an integral structure, the central member 5
0はパイプ状ではなく、中実のロッドとなっている。 0 is not a pipe-shaped, and has a solid rod.

【0025】図10は図5、図6、図7、図8および図9に示した実施例の実施時の状態を示す概略図である。 FIG. 10 is 5, 6, 7, is a schematic diagram showing a state of implementation when the embodiment shown in FIGS.
図10で示すように、端部材51につけられた小さな切れ目55から消息子91を盲端となっている端部材の終端53まで挿入し、消息子91の把持部92をもって上涙点11や下涙点12から総涙小管15、涙嚢16、鼻涙管17を経て下鼻道まで端部材の終端53を挿入する。 As shown in Figure 10, and inserted through a small cut 55 attached to the end member 51 an anti-son 91 to the end 53 of the end member has a Mekuratan, upper punctum 11 and the lower with the grip portion 92 of the vanishing son 91 total lacrimal canaliculus 15 from the punctum 12, lacrimal sac 16, inserting the end 53 of the end member to the bottom meatus through the nasolacrimal duct 17.

【0026】図11は図5、図6、図7、図8、図9および図10に示した実施例の涙道内における留置状態を示した概念図である。 FIG. 11 is 5, 6, 7, 8, is a conceptual diagram illustrating an indwelling state of the lacrimal duct of the embodiment shown in FIGS.

【0027】図5の実施例の製造方法を説明する。 [0027] describing the manufacturing method of the embodiment of FIG. まず、前述した寸法及び硬さを有する中央部材50と端部材51と連結部材71を準備する。 First, a connecting member 71 and the central member 50 and the end member 51 having a size and hardness mentioned above. 連結部材71の両端60を端部材51の開放端61と中央部材の端62に挿入し、シリコーン糊で接着する。 The ends 60 of the connecting member 71 is inserted into the end 62 of the open end 61 and the central member of the end member 51 are bonded with silicone glue. 中央部材50の両端6 Both ends 6 of the central member 50
2と端部材53の開放端61は連結部71になめらかに移行するようにエッジを削り、段差をなくする。 The open end 61 of the 2 and the end member 53 cutting edges so as to smoothly transition to the connecting portion 71 eliminates a step. 次に、 next,
端部材の開放端の近くに軸芯方向に沿って0.3〜0. 0.3 to 0 along the axial direction near the open end of the end member.
7mmの切れ目55を形成する。 Forming a cut 55 of 7 mm. さらにセンタリングに便利なように、挿管器具の中央部にセンタ印59を設ける。 As more convenient to centering, it provided the center mark 59 in the central portion of the intubation device. センタ印59で挿管器具が涙道内に正しく挿入されたかどうかを確認することができる。 Intubation device in the center mark 59 can be confirmed whether it has been properly inserted into the lacrimal duct. 図9に示すように、上下涙点の間にセンタ印59がくるように留置を行えばよい。 As shown in FIG. 9 may be performed indwelling as center mark 59 comes between the upper and lower puncta. また盲端53から10mmの部分にも印57 The mark also part of 10mm from the blind end 53 57
を設ける。 The provision. 印57は挿管器具挿入時の目安として利用するためのもので、大体10mmの涙小管の長さに合わせて設けると都合がよい。 Indicia 57 is for use as a guide during insertion intubation device, it is convenient to provide in accordance with the length of approximately 10mm canaliculae.

【0028】図12の実施例は、盲端部53は亀頭状に厚肉になっており、亀頭状部の最大径(m)は1.05 The embodiment of FIG. 12, Mekuratan unit 53 has become a thick glans shape, the maximum diameter of the glans-like portion (m) is 1.05
〜1.25mmで、望ましくは1.05〜1.2mm、 In ~1.25mm, preferably 1.05~1.2mm,
最適には1.08〜1.12mmの範囲に設定できる。 And most can be set in the range of 1.08~1.12mm.
亀頭状部53の肉厚(n)は0.2〜0.5mmであるが、望ましくは0.25〜0.45mm、最適には0. Thickness of Kameatamajo section 53 (n) but is 0.2 to 0.5 mm, preferably 0.25 to 0.45 mm, optimally 0.
3〜0.4mmである。 It is 3~0.4mm. 亀頭状部53の先端の長さ(e)は0.2〜1.5mmであるが、望ましくは0. Length of the tip of the Kameatamajo section 53 (e) is a 0.2 to 1.5 mm, preferably 0.
3〜1.0mm、最適には0.4〜0.6mmである。 3~1.0mm, optimally 0.4~0.6mm.
亀頭状部53の中央の長さ(d)は0.2〜1.5m Center in the length of Kameatamajo section 53 (d) is 0.2~1.5m
m、望ましくは0.3〜1.0mm、最適には0.4〜 m, preferably 0.3 to 1.0 mm, optimally 0.4
0.7mmである。 It is 0.7mm. また亀頭状部53の他端の長さ(q)は0.2〜20mm、望ましくは0.3〜5m The length of the other end of the glans-like portion 53 (q) is 0.2 to 20 mm, preferably 0.3~5m
m、最適には0.5〜3mmである。 m, and most preferably a 0.5~3mm.

【0029】図13はさらに他の実施例で、図12の実施例と同じ外形のものを涙道内に挿入した状態を示す概念図であるが、中央部材50の中央部30に薬物を含ませている。 FIG. 13 still another embodiment is a conceptual view showing a state in which was inserted into the lacrimal duct of the same outer shape as the embodiment of FIG. 12, contained the drug in the central portion 30 of the central member 50 ing.

【0030】図14はさらに他の実施例を示すもので、 [0030] Figure 14 and further illustrating the alternative embodiment,
中央部材50の外径が端部材51の外径より小さく、連結部材71の外径より大きなパイプ材で形成されているが、端部材51と連結部材71は図5に示した実施例と同じ範囲に設定でき、中央部材50の外径、内径、肉厚は各々、0.4〜1.0mm、0.3〜0.6mm、 The outer diameter of the central member 50 is smaller than the outer diameter of the end member 51, it is formed in the larger pipe material than the outer diameter of the connecting member 71, connecting member 71 and the end member 51 are the same as the embodiment shown in FIG. 5 range can be set to an outer diameter of the central member 50, an inner diameter, wall thickness, respectively, 0.4 to 1.0 mm, 0.3 to 0.6 mm,
0.1〜0.35mmであるが、望ましくは各々、0. It is a 0.1~0.35Mm, each desirably 0.
5〜0.9mm、0.4〜0.5mm、0.15〜0. 5~0.9mm, 0.4~0.5mm, 0.15~0.
25mmで、最適には各々、0.6〜0.8mm、0. In 25mm, the optimum each to, 0.6~0.8mm, 0.
4〜0. 4-0. . 48mm、0.18〜0.23mmの範囲に設定できるが、中央部材50のしなやかさについては、 48 mm, can be set in the range of 0.18~0.23Mm, the flexibility of the central member 50,
図5に示した実施例と同様の範囲に設定できる。 It can be set in the same range as the embodiment shown in FIG.

【0031】図15はさらに他の実施例の断面図で、図14に示した実施例と同じ外形を示すが、中央部材50 FIG. 15 is a further cross-sectional view of another embodiment, showing the same outer the embodiment shown in FIG. 14, the central member 50
がパイプ材でなく中実のロッドで形成されている。 There are formed in the solid rod rather than a pipe material.

【0032】図16は図14と図15に示した実施例の外形を示す斜視図である。 [0032] FIG. 16 is a perspective view showing an outer shape of the embodiment shown in FIGS. 14 and 15.

【0033】図17はさらに他の実施例を示す断面図で、盲端部53が亀頭状に厚肉になっており、さらに厚さ0.05〜0.2mmのステンレス94で補強しているが、その点を除くと外形は図16に示したものと同じである。 [0033] In cross section 17 showing a further embodiment, Mekuratan portion 53 has become a thick the glans shape, it is reinforced further by stainless 94 thick 0.05~0.2mm but external excluding the point is the same as that shown in FIG. 16.

【0034】図18はさらに他の実施例の断面と、その最適な1例の寸法と硬さを示す図であるが、中央部材5 [0034] Although FIG. 18 shows still a cross section of another embodiment, the dimensions and hardness of the optimum example, the central member 5
0は端部材51より小さい外径のパイプ材で形成されており、中央部材の中央部に連結部材71と同じ直径の中実のロッド72が介在し、中央部材50が左右の2つに分かれている。 0 is formed of a pipe material of smaller outer diameter end member 51, and interposed solid rod 72 of the same diameter as the connecting member 71 in the central portion of the central member, the central member 50 is divided into two right and left ing. ロッド72の長さは2〜6mmで、望ましくは3〜5mm、最適には3.5〜4mmに設定できる。 The length of the rod 72 is 2 to 6 mm, preferably 3 to 5 mm, and most can be set 3.5~4Mm. ロッド72と中央部材50の移行部63は1mmで傾斜をなしてなめらかに移行している。 Transition portion 63 of the rod 72 and the central member 50 is smoothly migrate at an inclination with 1 mm.

【0035】図19はさらに他の実施例を示す断面図で、図18に示した実施例の中央部材50の部分をパイプ材でなく中実のロッドとしたもので、盲端部53は図17で示したようにステンレス94で補強している。 [0035] In cross section 19 showing a further embodiment, a portion of the central member 50 of the embodiment shown in FIG. 18 which was a solid rod rather than a pipe material, Mekuratan 53 Figure It is reinforced with stainless steel 94 as shown in 17.

【0036】図20は図18と図19に示した実施例の外形を示す斜視図である。 [0036] FIG. 20 is a perspective view showing an outer shape of the embodiment shown in FIGS. 18 and 19.

【0037】図21はさらに他の実施例を示しているが、中央部材50と端部材51はパイプ材で形成され、 [0037] Although FIG. 21 shows still another embodiment, the central member 50 and the end member 51 is formed of a pipe material,
中央部材50の外径は端部材51と同じで、中央部材5 The outer diameter of the central member 50 is the same as the end member 51, the central member 5
0の中央部に連結部材71と同じ直径の中実のロッド7 0 of the central portion to the connecting member 71 and the solid rod 7 of the same diameter
2が介在し中央部材50が左右の2つに分かれ、ロッド72と中央部材50の境界部63は長さ1mmで段をなさないようになめらかに移行している。 2 is a central member 50 interposed is divided into two right and left boundaries 63 of the rod 72 and the central member 50 are smooth transition so as not made a step length 1 mm.

【0038】図22はさらに他の実施例であるが、外形は図20に示した実施例と同じであるが、中央部材50 [0038] Although FIG. 22 is a still another embodiment, the outer shape is the same as the embodiment shown in FIG. 20, the central member 50
がパイプ材でなく中実のロッドでできている。 There has been made of solid rod instead of the pipe material.

【0039】図23は図21と図22の外形を示した斜視図である。 [0039] FIG. 23 is a perspective view showing the outline of FIGS. 21 and 22.

【0040】図24は図21と図22に示した実施例の実施時の状態を示す概略図であるが、小さな切れ目55 [0040] Although FIG. 24 is a schematic diagram showing a state of implementation when the embodiment shown in FIGS. 21 and 22, a small cut 55
から盲端53まで消息子91が挿入されている。 Extinguishing son 91 is inserted from up blind end 53.

【0041】図25は図21と図22に示した実施例を涙道内に挿入した状態を示す概念図である。 FIG. 25 is a conceptual diagram showing a state of inserting the lacrimal duct to the embodiment shown in FIGS. 21 and 22. 図26はさらに他の実施例で、図25に示した端部材51の鼻涙管の中の部分31に薬物を含ませている。 Figure 26 is yet another embodiment, the drug moistened with the portion 31 in the nasolacrimal duct end member 51 shown in FIG. 25.

【0042】図27はさらに他の実施例で、中央部材5 [0042] Figure 27 yet another embodiment, the central member 5
0の外径は0.9〜1.4mmで、望ましくは1.0〜 The outer diameter of 0 is 0.9~1.4Mm, preferably 1.0 to
1.35mmで、最適には1.1〜1.3mmの範囲に設定できるが、その中央部材50の外径は端部材51の外径より0.1〜0.3mm大きなパイプ材で形成されており、中央部材50の中央に介在するロッド72により左右に分かれている。 In 1.35 mm, and most can be set in the range of 1.1~1.3Mm, the outer diameter of the central member 50 is formed of a 0.1~0.3mm larger pipe than the outer diameter of the end member 51 and it is divided into right and left by the rod 72 interposed in the middle of the central member 50. 中央部材50はパイプ材の代わりにハニカム構造や図28に示すように中実のロッドでもよい。 Central member 50 may be a solid rod as shown in the honeycomb structure and Fig. 28 in place of the pipe member.

【0043】図29はさらに他の実施例で、図27と図28に示した実施例と同じ外径のものをを涙道内に挿入した状態を示す概念図であるが、上涙小管13、下涙小管14、総涙小管15の中にある中央部材50の部分3 [0043] Figure 29 is a further embodiment, is a conceptual view showing a state in which was inserted into the lacrimal duct of the same outer diameter as the embodiment shown in FIGS. 27 and 28, the upper canaliculus 13, lower lacrimal canaliculus 14, part 3 of the central member 50 which is in the total canaliculus 15
2に薬物を含ませてある。 It is included the drug 2.

【0044】図30に示すように、薬物放出装置25は薬物コア22である薬物貯蔵部22と薬物放出膜21と支持体24からなる。 As shown in FIG. 30, the drug release device 25 becomes the drug reservoir 22 and the drug release layer 21 is a drug core 22 from the support 24. 緑内障治療のための薬物放出装置25は従来のオキュサート25と同じ構造であるが、オキュサート25の1/2から1/3の大きさであり、図31に示すように支持体24に巻きぐせをつけてあり、 Although the drug release device 25 for treating glaucoma has the same structure as conventional Okyusato 25, the magnitude of 1/3 to 1/2 of Okyusato 25, the habit around the support 24 as shown in FIG. 31 Yes wearing,
チューブの中央部材50の中央に着脱できるようになっている。 It has to be detached in the middle of the central member 50 of the tube. とくに図20と図23に示した外形を有するものは、中央部材50が左右の2つに分かれており、図3 In particular Figure 20 and having an outer shape as shown in FIG. 23, the central member 50 is divided into two left and right, Fig. 3
1と図32に示すように、薬物放出装置25を巻きつけるのに適している。 As shown in 1 and 32, it is suitable for winding the drug release device 25. すなわち図30に示した薬物放出装置25の大きさは 2×4.5mm〜3×7mmで、薬物放出膜21はエチレンビニルアセテート共重合体からなる高分子膜からなり、辺縁部の支持体24もエチレンアセテート共重合体からなる。 That is, in magnitude 2 × 4.5mm~3 × 7mm drug release device 25 shown in FIG. 30, drug release film 21 is made of a polymer film consisting of ethylene vinyl acetate copolymer, support marginal portion 24 also comprising an ethylene acetate copolymer. 薬物貯蔵部22にはオキュサート25と同じくピロカルピンコアが含まれるが、 While the drug reservoir 22 contains also pilocarpine core and Okyusato 25,
塩酸ピロカルピンとアルギン酸を含んだ製剤である。 It is a preparation containing pilocarpine hydrochloride and alginic acid. オキュサート25と異なり、本発明における薬物放出装置25においては、支持体24を白色顔料で染める必要はなく、ピロカルピンコアの代わりに他の薬物コアの薬物放出装置25を取り付けたものも使用される。 Unlike Okyusato 25, the drug release device 25 of the present invention need not dye the support 24 with white pigment, it is also used those attached drug release device 25 of another drug core instead of pilocarpine core. また両端部材51の全体、中央部材50の全体、連結部材71に薬物を含ませたものも薬物放出装置として使用される。 The entire end members 51, the whole of the central member 50, even those contained drug to the connecting member 71 is used as a drug release device.

【0045】図4に示したチューブ先端部の壁42が消息子91の先端93で突き破られることがある。 The wall 42 of the tube distal portion shown in FIG. 4 is to be pierced by the tip 93 of the extinguishing son 91. このチューブの突き抜け事故ができるだけ起こらないように、 As penetration accident of this tube is not as much as possible occur,
チューブの盲端部53をさらに強固なものになるように改良した本発明のさらに他の実施例のそれぞれを図33 Figure Each of yet another embodiment of the present invention which is improved so as to become more robust as the blind end 53 of the tube 33
〜42に示す。 Shown in to 42.

【0046】図33に示す盲端部の先端の長さ(e)は0.5〜2.0mm、望ましくは0.75〜1.5m The length of the tip of the blind end portion shown in FIG. 33 (e) is 0.5 to 2.0 mm, preferably 0.75~1.5m
m、最適には0.9〜1.2mmの範囲で設定できる。 m, and most can be set in the range of 0.9 to 1.2 mm.
盲端部の長さ(j´)は0.3〜1.2mm、望ましくは0.5〜1.0mm、最適には0.6〜0.9mmの範囲に設定できる。 The length of the blind end portion (j') is 0.3 to 1.2 mm, preferably 0.5 to 1.0 mm, and most can be set in the range of 0.6~0.9Mm. 盲端部の長さ(i´)は0.05〜 The length of the blind end portion (i') is 0.05
0.4mm、望ましくは0.1〜0.35mm、最適には0.2〜0.3mmの範囲に設定できる。 0.4 mm, preferably 0.1~0.35Mm, optimally be set in the range of 0.2 to 0.3 mm. 盲端部の内腔はステンレス補強部材94で補強しているが、ステンレス補強部材の肉厚(f´)は0.02〜0.1mm、 Although the lumen of the blind end portion is reinforced with stainless steel reinforcing member 94, the thickness of the stainless steel reinforcing member (f') is 0.02 to 0.1 mm,
望ましくは0.023〜0.05mm、最適には0.0 Desirably 0.023~0.05Mm, optimally 0.0
24〜0.03mmの範囲に設定できる。 It can be set in the range of 24~0.03mm. ステンレス補強部材94の長さ(g´)は0.5〜10mm、望ましくは1〜5mm、最適には1.5〜3mmの範囲に設定できる。 The length of the stainless steel reinforcing member 94 (g ') is 0.5 to 10 mm, preferably 1 to 5 mm, and most can be set in the range of 1.5 to 3 mm. ステンレス補強部材94の長さ(h´)は0. The length of the stainless steel reinforcing member 94 (h') 0.
15〜0.4mm、望ましくは0.2〜0.35mm、 15~0.4mm, preferably 0.2~0.35mm,
最適には0.25〜0.3mmの範囲に設定できる。 And most can be set in the range of 0.25~0.3mm. ステンレス補強部材94が存在する部分の内腔の直径(d The diameter of the lumen of a portion of stainless reinforcing member 94 is present (d
´)は0.3〜0.6mm、望ましくは0.35〜0. ') Is 0.3~0.6mm, preferably from 0.35 to 0.
5mm、最適には0.40〜0.47mmの範囲に設定できる。 5mm, and most can be set in the range of 0.40~0.47mm. 端部材51の肉厚(c)は0.15〜0.5m The thickness of the end member 51 (c) is 0.15~0.5m
m、望ましくは0.2〜0.3mm、最適には0.2〜 m, preferably 0.2 to 0.3 mm, 0.2 to optimally
0.27mmの範囲に設定できる。 It can be set in the range of 0.27mm. 端部材51の外径(a)は0.6〜1.2mm、望ましくは0.8〜1. Outer diameter of the end member 51 (a) is 0.6 to 1.2 mm, preferably 0.8 to 1.
1mm、最適には0.9〜1.0mmの範囲に設定できる。 1mm, and most can be set in the range of 0.9~1.0mm. 端部材51の内径(b)は0.3〜0.6mm、望ましくは0.35〜0.5mm、最適には0.4〜0. The inner diameter of the end member 51 (b) is 0.3 to 0.6 mm, preferably 0.35~0.5Mm, optimally from 0.4 to 0.
45mmの範囲に設定できる。 It can be set in the range of 45mm.

【0047】図34は本発明のさらに他の実施例の盲端部の断面とその最適な1例の寸法を示す断面図である。 [0047] Figure 34 is a sectional view showing the dimensions of a further cross-section of the blind end portion of the embodiment and its best example of the present invention.

【0048】図35は本発明のさらに他の実施例の盲端部の断面とその最適な1例の寸法を示す断面図である。 [0048] Figure 35 is a sectional view showing still sectional and its best example dimensions of the blind end portion of another embodiment of the present invention.

【0049】図36、37、38、39はそれぞれ本発明のさらに他の実施例を示す断面図で、端部材51の両端53がステンレス補強部材94で補強されている。 [0049] Figure 36, 37, 38, 39 is a sectional view showing still another embodiment of the present invention, respectively, both ends 53 of the end member 51 is reinforced with stainless steel reinforcing member 94.

【0050】図40は本発明のさらに他の実施例の断面とその最適な1例の寸法を示す図で、盲端部53がステンレス補強部材94で補強されている。 [0050] Figure 40 is a view showing yet a section and its best example dimensions of the other embodiments of the present invention, Mekuratan portion 53 is reinforced with stainless steel reinforcing member 94.

【0051】図41のAは本発明のさらに他の実施例の外形を示す斜視図で、図41のBはその断面図である。 [0051] A of FIG. 41 is a perspective view showing still outline of another embodiment of the present invention, B in FIG. 41 is a sectional view thereof.
図41のBに示すように、盲端部53はステンレス補強部材94で補強されている。 As shown in B of FIG. 41, Mekuratan portion 53 is reinforced with stainless steel reinforcing member 94. その挿管器具の全長(l) The total length of the intubation device (l)
は一般に50〜130mm、望ましくは90〜120m In general 50~130mm is desirably 90~120m
m、最適には95〜110mmの範囲に設定できる。 m, and most can be set in the range of 95~110Mm. また端部材51の長さ(i)は10〜60mmであるが、 The length of the end member 51 (i) is a 10 to 60 mm,
望ましくは30〜45mm、最適には33〜40mmの範囲に設定できる。 Desirably 30~45Mm, optimally be set in the range of 33~40Mm. 中央部材50の長さ(j)は15〜 The length of the central member 50 (j) is 15
35mmであるが、望ましくは20〜35mm、最適には20〜30mmの範囲に設定できる。 It is a 35 mm, preferably 20 to 35 mm, and most can be set in the range of 20 to 30 mm. 中央部材50は内腔のないロッドからなり、その外径は0.4〜0.7 Central member 50 is a rod without lumen, an outer diameter 0.4 to 0.7
mmで、望ましくは0.45〜0.6mm、最適には0.5〜0.6mmの範囲に設定できる。 In mm, preferably 0.45~0.6Mm, optimally be set in the range of 0.5-0.6 mm. 端部材の外径(a)と内径(b)については図33、34、35で示した通りである。 The outer diameter of the end member (a) and the inner diameter (b) is as shown in FIG. 33, 34 and 35. 端部材51と中央部材50の境界部6 Boundary portion of the end member 51 and central member 50 6
1はなめらかに移行し、その長さ(h)は0.5〜17 1 is a smooth transition, the length (h) is 0.5 to 17
mmであるが、望ましくは1〜5mm、最適には2〜4 It is a mm, preferably 1 to 5 mm, and optimally 2 to 4
mmである。 A mm.

【0052】図33、34、35で示した本発明の実施例の盲端部53の改良は、図5、6、7、8、9、1 [0052] improvement of the blind end 53 of the embodiment of the present invention shown in FIG. 33, 34 and 35, FIG 5,6,7,8,9,1
0、11、14、15、16、18、19、20、2 0,11,14,15,16,18,19,20,2
1、22、23、24、25、26、27、28、2 1,22,23,24,25,26,27,28,2
9、31、32に示したそれぞれの実施例に対しても適応することができる。 It can be adapted for each of the embodiments shown in 9,31,32.

【0053】 [0053]

【発明の効果】本発明の好適な涙道挿管器具によれば、 According to a preferred lacrimal duct intubation device of the present invention,
連結部材71の外径が中央部材50や端部材51より小さくなっているので、その中央部をピンセットで持ち上げると逆U字型になるが、強い逆U字型ではなく適度な逆U字型になるため、留置後に涙点や涙小管に裂傷が生じる恐れは極めて小さい。 Since the outer diameter of the connecting member 71 is smaller than the central member 50 and the end member 51, becomes an inverted U-shape lifting its central portion with a pair of tweezers, moderate inverted U-shaped rather than strong inverse U-shape to become, risk of laceration occurs in the punctum or canaliculus after indwelling is very small. また中央部材50は従来のものより10〜20(shore A)ほど硬くなっており、引っ張られても細くなりにくいため、留置後に涙点や涙小管の裂傷が起こりにくい。 The central member 50 has become hard as 10 to 20 than that of the conventional (shore A), since it is difficult narrows be pulled, less prone to tearing of the punctum and canaliculus after placement. また連結部材71は端部材51や中央部材50よりも細くしなやかになっているため涙道内での安定性が高く、留置後のトラブルが非常に少ない。 The connecting member 71 is highly stable in the lacrimal duct because that is a supple thinner than the end members 51 and central member 50, is very small trouble after placement. また端部材51は硬い材質でできており、 The end member 51 is made of hard material,
消息子91により突き破られることが少なくなった。 Be pierced by the vanishing son 91 is low. さらに端部材51の盲端53を厚肉にして亀頭状とすることで、消息子91で突き破られることが一層少なくなった。 With glans shape by further blind end 53 of the end member 51 thicker, it becomes further reduced to pierced by extinguishing son 91.

【0054】また、さらに盲端部53をステンレス補強部材94で補強することにより、消息子91による突き抜け事故の恐れがなくなった。 [0054] Also, by further reinforcing the blind end 53 of a stainless reinforcing member 94, it is no longer a risk of accidents penetration by extinguishing son 91. 補強部材94は、ステンレスだけでなく他の金属やプラスチックで作ってもよい。 Reinforcing member 94 may be made of other metals or plastics as well as stainless steel.

【0055】また中央部材50の外径が端部材51の外径と同じか、それより太いものは、涙点プラグの代わりに使用することができる。 [0055] In addition or equal to the outer diameter of the outer diameter of the end member 51 of the central member 50, is thicker than that, it can be used instead of the punctal plug.

【0056】さらに中央部材50に緑内障薬をしみ込ませることにより、緑内障のためのドラグデリバリーシステムとして利用できる。 [0056] By impregnating the glaucoma drug more central member 50, it can be used as a drag delivery system for glaucoma.

【0057】ドラグデリバリーシステムとして中央部材50の太いものに薬物を含ませたものを使用すると、中央部材50が上下涙小管を塞ぐので、中央部材50に含ませている緑内障薬が放出されても涙液に含まれた薬物が涙道に流れてゆかないので、薬効は増大される。 [0057] The use of those contained the drug to those thick of the central member 50 as the drag delivery system, since the central member 50 blocks the vertical canaliculus, even glaucoma drugs are included in the central member 50 is released since the drug contained in the tear is not Yuka flow in the canal tears, efficacy is increased. さらに端部材51に薬物を含ませることにより涙嚢や鼻涙管に対するドラグデリバリーシステムとして利用できる。 It can be used as the drag delivery system for the lacrimal sac and nasolacrimal duct by including drug more end members 51.
中央部材50や端部材51に抗生物質や抗菌剤を含ませたものを涙道閉塞の治療のための涙道ステントとして使用すると、感染の予防や治療を同時に行うことができるので、治療効果は増強される。 With the center member 50 and the end member 51 that contained antibiotics and antibacterial agents as lacrimal stent for the treatment of lacrimal duct obstruction, it is possible to perform the prevention and treatment of infections at the same time, the therapeutic effect It is enhanced. また中央部材50や端部材51に5−FUなどの抗腫瘍剤を含ませたものを涙道閉塞の治療に用いると、抜去後に再閉塞が起こりにくくなる。 Also the use of those impregnated with anti-tumor agents such as 5-FU in the central member 50 and end member 51 in the treatment of lacrimal duct obstruction, reocclusion hardly occur after removal. 中央部材50にステロイド剤を含ませたものを使用すると、ぶどう膜炎の治療に役立つ。 With that contained a steroid to the central member 50, useful in the treatment of uveitis. また中央部材5 In addition, the central member 5
0に抗生物質や抗菌剤や抗ウイルス剤を含ませたものは、結膜炎や角膜炎の治療に役立つ。 0 to that contained antibiotics and antibacterial agents and antiviral agents are useful in the treatment of conjunctivitis and keratitis.

【0058】さらに、本発明の端部材51に全身疾患に効果のある薬物を含ませたものは、全身疾患治療に役立つ。 [0058] Furthermore, those in the edge member 51 of the present invention was included drugs that are effective in systemic diseases will help systemic diseases.

【0059】本発明による器具は、動物の涙道の長さや内腔の広さに応じて本発明の大型のものや小型のものを使用することにより、動物の涙道閉塞や緑内障やドライアイなどの治療に使用することができる。 [0059] device according to the invention, by the use of a large size ones and small of the present invention depending on the size of the length and the lumen of the animal lacrimal, animal lacrimal duct obstruction or glaucoma and dry eye it can be used in the treatment of such. また中央部材50の中央部に緑内障治療用のオキュサート25を巻きつける形で着脱自在にとりつけると、オキュサート25 Further, when attaching detachably the form winding the Okyusato 25 for treating glaucoma in a central portion of the central member 50, Okyusato 25
の眼表面における安定性がよくなり、オキュサート25 Stability is good in the eye surface, Okyusato 25
を紛失したり脱落したりしなくなり、オキュサート25 A longer or or falling off lost, Okyusato 25
による眼表面の刺激が少なくなるため、患者は異物感、 Since the stimulation of the ocular surface is reduced by, the patient is foreign body sensation,
充血、流涙、眼脂、眼痛を訴えることが少なくなる。 Hyperemia, tearing, eye discharge, is to sue the eye pain is less. 中央部材50の細いものは、必要ならば涙道内に2本挿入し、さらに涙道を拡張することも可能である。 Thin ones of the central member 50, if necessary to insert two on lacrimal duct, it is possible to further expand the canal tears.

【0060】なお、本発明は前述の実施例に限定されない。 [0060] The present invention is not limited to the aforementioned embodiments. たとえば、生体適合性がよければ端部材51は80 For example, the end member 51 If you're biocompatibility 80
(shore A)以上のさらに硬度の高い他のプラスチックでもよい。 (Shore A) or further may be another plastic high hardness. また所定のしなやかさが得られれば、 Also as long obtain a predetermined flexibility,
中央部材50はハニカム構造でもよい。 Central member 50 may be a honeycomb structure. また中央部材5 In addition, the central member 5
0に薬物放出装置25を巻きつけるのではなく、中央部材50に着脱できる薬物放出装置25を組み込む方法でもよい。 0 instead of winding the drug release device 25, or a method of incorporating a drug release device 25 that can be removably attached to the central member 50. 中央部材50に薬物放出装置25を装着する方法は、中央部材50や端部材51により涙道を狭くしたり閉じたりするので、放出された薬物は容易に涙道に排出されないため、眼に対する薬物の効果は長時間持続する。 Method of attaching a drug release device 25 to the central member 50, so or close to narrow the lacrimal duct by a central member 50 and end member 51, since the released drug is not easily discharged to the lacrimal duct, the drug to the eye the effect lasts for a long time.

【図面の簡単な説明】 BRIEF DESCRIPTION OF THE DRAWINGS

【図1】涙道を示す概略図。 FIG. 1 is a schematic diagram showing the road tears.

【図2】オキュサートの構造と構成を示す図。 FIG. 2 shows the structure and configuration of Okyusato.

【図3】従来の技術の問題点を説明するための概略説明図。 3 is a schematic explanatory view for explaining the problems of the prior art.

【図4】従来の技術の問題点を説明するための概略説明図。 Figure 4 is a schematic explanatory view for the problem is described in the prior art.

【図5】本発明による好適な涙道挿管器具の実施例を示す断面図。 Sectional view showing an example of a suitable lacrimal duct intubation instrument according the present invention; FIG.

【図6】本発明による涙道挿管器具の他の実施例を示す断面図。 Sectional view showing another embodiment of a lacrimal duct intubation instrument according the present invention; FIG.

【図7】図5と図6に示した実施例の外形を示す斜視図。 [7] FIG. 5 and a perspective view showing an outer shape of the embodiment shown in FIG.

【図8】本発明による涙道挿管器具のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of the lacrimal duct intubation instrument according the present invention; FIG.

【図9】本発明のさらに他の実施例を示す断面図。 FIG. 9 is a cross-sectional view showing still another embodiment of the present invention.

【図10】図5、図6、図7、図8および図9に示した実施例の実施時の状態を示す斜視図。 [10] FIGS. 5, 6, 7, a perspective view showing a state of implementation when the embodiment shown in FIGS.

【図11】図5、図6、図7、図8および図9に示した実施例を涙道内に挿入した状態を示す概念図。 [11] FIGS. 5, 6, 7, conceptual view showing a state in which the embodiment is inserted into the lacrimal duct shown in FIGS.

【図12】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of the present invention; FIG.

【図13】本発明のさらに他の実施例で、図12に示した実施例と同じ外形のものを涙道内に挿入した状態を示す概念図。 [13] In yet another embodiment of the present invention, conceptual view showing a state in which was inserted into the lacrimal duct of the same outer shape as the embodiment shown in FIG. 12.

【図14】本発明のさらに他の実施例を示す断面図。 FIG. 14 is a cross-sectional view showing still another embodiment of the present invention.

【図15】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of the present invention; FIG.

【図16】図14に示した実施例の外形を示す斜視図。 Figure 16 is a perspective view showing an outer shape of the embodiment shown in FIG. 14.

【図17】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of FIG. 17 the present invention.

【図18】本発明のさらに他の実施例を示す断面図であり、その最適な1例の寸法と硬さを示す。 [Figure 18] is a sectional view showing still another embodiment of the present invention, showing the dimensions and stiffness of the optimum example.

【図19】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of Figure 19 the present invention.

【図20】図18と図19に示した実施例の外形を示す斜視図。 [20] Figure 18 and a perspective view showing an outer shape of the embodiment shown in FIG. 19.

【図21】本発明のさらに他の実施例を示す断面図。 Figure 21 is a sectional view showing still another embodiment of the present invention.

【図22】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of FIG. 22 the present invention.

【図23】図21と図22に示した実施例の外形を示す斜視図。 [23] Figure 21 and a perspective view showing an outer shape of the embodiment shown in FIG. 22.

【図24】図21と図22に示した実施例の実施時の状態を示す概略図。 [24] Figure 21 and a schematic diagram showing a state of implementation when the embodiment shown in FIG. 22.

【図25】図28、図29および図30に示した実施例を涙道内に挿入した状態を示す概念図。 [25] Figure 28 a conceptual diagram showing a state of inserting the lacrimal duct to the embodiment shown in FIGS. 29 and 30.

【図26】本発明のさらに他の実施例で、図21と図2 [26] In yet another embodiment of the present invention, FIGS. 21 and 2
2に示した実施例と同じ外形のものを涙道内に挿入した状態を示す概念図。 Conceptual view showing a state in which was inserted into the lacrimal duct of the same outer shape as the embodiment shown in 2.

【図27】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of FIG. 27 the present invention.

【図28】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of FIG. 28 the present invention.

【図29】本発明のさらに他の実施例で、図27と図2 In yet another embodiment of FIG. 29 the present invention, FIGS. 27 and 2
8に示した実施例と同じ外形のものを涙道内に挿入した状態を示す概念図。 Conceptual view showing the inserted state lacrimal duct having the same outer shape as the embodiment shown in 8.

【図30】本発明の他の実施例を示す図で、(A)が巻きぐせのついた薬物放出装置をひろげた状態でその構成を示す図で、(B)がその薬物放出装置を分解した状態を示す図である。 In view showing another embodiment of FIG. 30 the present invention, a diagram showing the configuration in a state in which spread the drug release device with a habit of winding (A), (B) decomposing the drug release device it is a diagram illustrating a state.

【図31】図30に示した実施例の使用法を示す図で、 [31] a diagram showing method used in the embodiment shown in FIG. 30,
(A)が巻きぐせのついた薬物放出装置を示している。 (A) shows the curl marked with drug release device.
図5〜29に示した実施例にこの薬物放出装置を装着することができる。 It can be mounted the drug release device in the embodiment shown in FIG. 5 to 29. (B)が図7に示した実施例に薬物放出装置を装着した状態を示した斜視図で、(C)が図5 (B) is a perspective view showing a state of mounting the drug release device in the embodiment shown in FIG. 7, (C) in FIG. 5
に示されている実施例に薬物放出装置を装着した状態を示した断面図。 Cross-sectional view of the drug release apparatus shown mounted in the embodiment shown in.

【図32】図31に示した実施例を涙道内に挿入した状態を示す概念図。 Figure 32 is a conceptual diagram showing a state in which the embodiment is inserted into the lacrimal duct shown in FIG. 31.

【図33】本発明のさらに他の実施例の盲端部を示す断面図。 Figure 33 is a cross-sectional view showing still blind end portion of another embodiment of the present invention.

【図34】本発明のさらに他の実施例の盲端部の断面とその最適な1例の寸法を示す断面図。 Figure 34 is a cross-sectional view further showing a cross section and its best example dimensions of the blind end portion of another embodiment of the present invention.

【図35】本発明のさらに他の実施例の盲端部の断面とその最適な1例の寸法を示す断面図。 Figure 35 is a cross-sectional view further showing a cross section and its best example dimensions of the blind end portion of another embodiment of the present invention.

【図36】本発明のさらに他の実施例を示す断面図。 Figure 36 is a cross-sectional view showing still another embodiment of the present invention.

【図37】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of FIG. 37 the present invention.

【図38】本発明のさらに他の実施例を示す断面図。 Figure 38 is a cross-sectional view showing still another embodiment of the present invention.

【図39】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of FIG. 39 the present invention.

【図40】本発明のさらに他の実施例を示す断面図。 Sectional view showing still another embodiment of FIG. 40 the present invention.

【図41】本発明のさらに他の実施例を示す図で、 In view showing still another embodiment of FIG. 41 the present invention,
(A)がその外形を示す斜視図で、(B)がその断面図。 (A) is a perspective view showing the external shape, (B) is a cross-sectional view thereof.

【図42】図41に示した実施例の使用法の一例を示す図で、(A)が巻きぐせのついた薬物放出装置を示しており、(B)が薬物放出装置を装着した状態を示した斜視図で、(C)が薬物放出装置を装着した状態を示した断面図。 [Figure 42] a diagram showing an example of use of the embodiment shown in FIG. 41, a state marked with shows the drug release device, which is (B) fitted with a drug release device of habit winding is (A) a perspective view showing a cross-sectional view showing a state in which (C) is fitted with a drug release device.

【符号の説明】 DESCRIPTION OF SYMBOLS

11 上涙点 12 下涙点 13 上涙小管 14 下涙小管 15 総涙小管 16 涙嚢 17 鼻涙管 18 鼻孔 19 涙腺 20 薬物放出装置 21 薬物放出調節膜 21 高分子膜 21 エチレンビニルアセテート共重合体膜 21 薬物放出膜 22 薬物貯蔵部 22 ピロカルピンコア 23 間隙 24 白色支持体 24 支持体 25 オキュサート 25 薬物放出装置 30 上涙点と下涙点の間にある中央部材の中央部の、 11 upper punctum 12 lower punctum 13 above canaliculus 14 under canaliculus 15 total canaliculus 16 lacrimal sac 17 nasolacrimal duct 18 nostril 19 lacrimal 20 drug release device 21 drug release controlling membrane 21 polymer film 21 ethylene vinyl acetate copolymerization the central portion of the central member, between the coalesced film 21 drug release film 22 drug reservoir 22 pilocarpine core 23 gap 24 white support 24 support 25 Okyusato 25 drug release device 30 upper punctum and a lower punctum,
薬物を含んだ部分 31 鼻涙管の中にある端部材の、薬物を含んだ部分 32 涙小管の中にある中央部材の、薬物を含んだ部分 40 従来のチューブの中央のしなやかな部分 41 涙小管の裂傷 42 チューブ先端部の破れ 50 中央部材 51 端部材 53 終端部 53 盲端 53 亀頭状部 55 切り込み 55 切れ目 57 印 59 センター印 60 連結部材の両端 61 端部材の開放端 61 接着部分 62 中央部材の端 62 中央部材の両端 62 接着部分 71 連結部材 72 ロッド 91 消息子 92 消息子の把持部 93 消息子の先端 94 補強部材 End member which is in the inclusive portion 31 nasolacrimal duct drugs, central member is in the portion 32 canaliculus containing the drug portion 40 pliable portion 41 tears the center of a conventional tube containing the drug open end 61 bonded portion 62 central ends 61 end member lacerations 42 tubing end portion of the tear 50 central member 51 end member 53 terminating unit 53 blind end 53 Kameatamajo portion 55 cut 55 cut 57 marks 59 center marks 60 connecting member tubules end 62 central member ends 62 bonded portion 71 connecting member 72 the rod 91 extinguishing son 92 vanishing son gripper 93 vanishing son of the tip 94 reinforcing member members

Claims (25)

    【特許請求の範囲】 [The claims]
  1. 【請求項1】 2つの端部材(51)と、2つの端部材(51)の間に配置される中央部材(50)と、2つの端部材(51)の各々を中央部材(50)に連結する連結部材(71)を備えていて、端部材(51)の各々が消息子(91)を挿入するための切れ込み(55)を有し、パイプ状に形成されており、端部材(51)の終端が盲端(53)になっていて、連結部材(71)は端部材(51)及び中央部材(50)よりしなやかで、連結部材(71)の外径は端部材(51)及び中央部材(5 And 1. A two end members (51), a central member disposed between the two end members (51) (50), each of the two end members (51) to the central member (50) have a connection to the connecting member (71) has a notch (55) for each end member (51) is inserted an anti-son (91), is formed in a pipe shape, an end member (51 end of) they become blind end (53), the connecting member (71) is supple than the end member (51) and the central member (50), the outer diameter of the connecting member (71) is an end member (51) and the central member (5
    0)の外径より小さくなっていることを特徴とする涙道挿管器具。 Lacrimal intubation device, characterized in that is smaller than the outside diameter of 0).
  2. 【請求項2】 連結部材(71)のショア硬さが20〜 Wherein the Shore hardness of the connecting member (71) is 20
    80(shoreA)であり、端部材(51)のショア硬さが60〜80(shore A)であり、中央部材(50)のショア硬さが20〜80(shore A) 80 is a (Shorea), a Shore hardness of the end member (51) is 60-80 (shore A), Shore hardness of the central member (50) is 20 to 80 (shore A)
    であることを特徴とする請求項1に記載の涙道挿管器具。 Lacrimal intubation instrument of claim 1, characterized in that.
  3. 【請求項3】 連結部材(71)のショア硬さが40〜 3. A 40 Shore hardness of the connecting member (71)
    80(shoreA)であり、端部材(51)のショア硬さが60〜80(shore A)であり、中央部材(50)のショア硬さが50〜80(shore A) 80 is a (Shorea), a Shore hardness of the end member (51) is 60-80 (shore A), Shore hardness of the central member (50) is 50 to 80 (shore A)
    であることを特徴とする請求項1に記載の涙道挿管器具。 Lacrimal intubation instrument of claim 1, characterized in that.
  4. 【請求項4】 連結部材(71)のショア硬さが50〜 4. A 50 Shore hardness of the connecting member (71)
    60(shoreA)であり、端部材(51)のショア硬さが75〜80(shore A)であり、中央部材(50)のショア硬さが60〜75(shore A) 60 is a (Shorea), a Shore hardness of the end member (51) is 75-80 (shore A), Shore hardness of the central member (50) is 60 to 75 (shore A)
    であることを特徴とする請求項1に記載の涙道挿管器具。 Lacrimal intubation instrument of claim 1, characterized in that.
  5. 【請求項5】 連結部材(71)と端部材(51)と中央部材(50)が一体物として構成されている請求項1 5. A coupling member (71) and claim the end member (51) the central member (50) is configured in one piece 1
    〜4のいずれか1項に記載の涙道挿管器具。 Lacrimal duct intubation device according to any one of to 4.
  6. 【請求項6】 中央部材(50)の中央部の3〜5mm 6. 3~5mm the central portion of the central member (50)
    の部分が細くなっていることを特徴とする請求項1〜5 Claims 1 to 5, characterized in that the parts are thinner
    のいずれか1項に記載の涙道挿管器具。 Lacrimal duct intubation device according to any one of.
  7. 【請求項7】 両端部材(51)の終端が亀頭状にふくらみ厚肉になっていることを特徴とする請求項1に記載の涙道挿管器具。 7. A lacrimal intubation instrument of claim 1, the end of the end members (51) is characterized in that it is thicker bulge in glans shape.
  8. 【請求項8】 中央部材(50)の外径が端部材(5 8. central outer diameter end member of the member (50) (5
    1)の外径と同じか、それよりも大きく、涙点プラグとして利用する形になっていることを特徴とする請求項1 Equal to the outer diameter of 1), greater than, claim, characterized in that is in the form used as punctal plug 1
    〜7のいずれか1項に記載の涙道挿管器具。 Lacrimal duct intubation device according to any one of to 7.
  9. 【請求項9】 中央部材(50)が軟らかい材質でできており、中央部材(50)に薬物を含ませてドラグデリバリーシステムとして利用する構成にした請求項1〜8 9. is able in soft material the central member (50), according to claim 1 to 8 was configured to use as a drag delivery system by including the drug to the central member (50)
    のいずれか1項に記載の涙道挿管器具。 Lacrimal duct intubation device according to any one of.
  10. 【請求項10】 端部材(51)に薬物を含ませ、涙嚢や鼻涙管に対するドラグデリバリーシステムとした請求項1〜8のいずれか1項に記載の涙道挿管器具。 10. A drug moistened with the end member (51), lacrimal intubation device as claimed in any one of claims 1 to 8 as a drag delivery system for the lacrimal sac and nasolacrimal duct.
  11. 【請求項11】 両端部材(51)の全体と中央部材(50)の全体と連結部材(71)の全体に薬物を含ませた請求項1〜8のいずれか1項に記載の涙道挿管器具。 11. end members (51) of the total and the central member (50) throughout the connecting member (71) of the lacrimal intubation according to any one of claims 1 to 8 contained the drug to total instrument.
  12. 【請求項12】 中央部材(50)の中央に薬物放出装置(25)を巻きつけてドラグデリバリーシステムとした請求項1〜11のいずれか1項に記載の涙道挿管器具。 12. lacrimal intubation device as claimed in any one of claims 1 to 11 as a drag delivery system by winding drug release device (25) in the middle of the central member (50).
  13. 【請求項13】 オキュサート(25)を中央部材(5 13. Okyusato (25) the central member (5
    0)の中央に着脱自在に取りつける請求項1〜11のいずれか1項に記載の涙道挿管器具。 Lacrimal intubation device as claimed in any one of claims 1 to 11, center removably attach 0).
  14. 【請求項14】 盲端部(53)をステンレス材(9 14. Mekuratan portion (53) stainless steel (9
    4)で補強している請求項1〜11のいずれか1項に記載の涙道挿管器具。 Lacrimal intubation device as claimed in any one of claims 1 to 11 which is reinforced by 4).
  15. 【請求項15】 連結部材(71)と端部材(51)と中央部材(50)がシリコーンゴムで形成されていることを特徴とする請求項1〜12のいずれか1項に記載の涙道挿管器具。 15. The connecting member (71) and end member (51) and the central member (50) is lacrimal according to any one of claims 1 to 12, characterized in that it is formed of silicone rubber intubation device.
  16. 【請求項16】 2つの端部材(51)と、2つの端部材(51)の間に配置される中央部材(50)を備えていて、端部材(51)および中央部材(50)の少くとも一方に薬物を含ませていることを特徴とする涙道挿管器具。 And 16. Two end members (51), provided with a central member disposed between the two end members (51) (50), end member (51) and at least the central member (50) lacrimal intubation device, characterized in that it drug moistened with the one also.
  17. 【請求項17】 2つの端部材(51)の各々を中央部材(50)に連結する連結部材(71)を備えていて、 17. Each of the two end members (51) comprise a connecting member (71) connecting the central member (50),
    連結部材(71)のショア硬さが20〜80(shor Shore hardness of the connecting member (71) is 20 to 80 (shor
    e A)であり、端部材(51)のショア硬さが60〜 A e A), 60 to Shore hardness of the end member (51)
    80(shore A)であり、中央部材(50)のショア硬さが20〜80(shoreA)であることを特徴とする請求項16に記載の涙道挿管器具。 80 is a (shore A), lacrimal intubation instrument of claim 16, Shore hardness of the central member (50) is characterized in that it is a 20 to 80 (Shorea).
  18. 【請求項18】 中央部材(50)の中央部の3〜5m 18. the central portion of the central member (50) 3 to 5 m
    mの部分が細くなっていることを特徴とする請求項16 Claim, characterized in that the m portions of the are tapered 16
    又は17に記載の涙道挿管器具。 Or lacrimal intubation device according to 17.
  19. 【請求項19】 両端部材(51)の終端が亀頭状にふくらんだ盲端になっていて厚肉になっていることを特徴とする請求項16〜18のいずれか1項に記載の涙道挿管器具。 19. lacrimal according to any one of claims 16 to 18 termination is characterized that it is thicker they become blind end bulging glans shaped end members (51) intubation device.
  20. 【請求項20】 両端部材(51)と中央部材(50) 20. end members (51) and the central member (50)
    と連結部材(71)に薬物を含ませた請求項17に記載の涙道挿管器具。 Lacrimal intubation instrument of claim 17 in which the drug moistened with the connecting member (71) and.
  21. 【請求項21】 中央部材(50)の中央に薬物放出装置(25)を巻きつけてドラグデリバリーシステムとした請求項16〜19のいずれか1項に記載の涙道挿管器具。 21. lacrimal intubation device as claimed in any one of claims 16 to 19 in which the drag delivery system by winding drug release device (25) in the middle of the central member (50).
  22. 【請求項22】 オキュサート(25)を中央部材(5 22. Okyusato (25) the central member (5
    0)の中央に着脱自在に取りつける請求項16〜19のいずれか1項に記載の涙道挿管器具。 Lacrimal intubation device as claimed in any one of claims 16 to 19 center removably attach 0).
  23. 【請求項23】 盲端部(53)をステンレス材(9 23. Mekuratan portion (53) stainless steel (9
    4)で補強している請求項19に記載の涙道挿管器具。 Lacrimal intubation instrument of claim 19 which is reinforced by 4).
  24. 【請求項24】 連結部材(71)と端部材(51)と中央部材(50)がシリコーンゴムで形成されていることを特徴とする請求項17に記載の涙道挿管器具。 24. lacrimal intubation instrument of claim 17, the connecting member (71) and end member (51) and the central member (50) is characterized in that it is formed of silicone rubber.
  25. 【請求項25】 チューブの盲端部の内部をステンレス等の補強部材で補強した請求項1〜24のいずれか1項に記載の涙道挿入管器具。 25. lacrimal insertion tube device according to any one of claims 1 to 24 inside of the blind end of the tube was reinforced by the reinforcing member such as stainless steel.
JP8214093A 1996-07-26 1996-07-26 Lacrimal duct insertion appliance Granted JPH1033584A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8214093A JPH1033584A (en) 1996-07-26 1996-07-26 Lacrimal duct insertion appliance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8214093A JPH1033584A (en) 1996-07-26 1996-07-26 Lacrimal duct insertion appliance

Publications (1)

Publication Number Publication Date
JPH1033584A true JPH1033584A (en) 1998-02-10

Family

ID=16650118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8214093A Granted JPH1033584A (en) 1996-07-26 1996-07-26 Lacrimal duct insertion appliance

Country Status (1)

Country Link
JP (1) JPH1033584A (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988844A2 (en) * 1998-08-27 2000-03-29 MLC Limited Company Apparatus for intubation of lacrimal duct
EP1048275A3 (en) * 1999-04-28 2001-08-22 MLC Limited Company Apparatus for intubation of lacrimal duct
JP2005328922A (en) * 2004-05-18 2005-12-02 M L C:Kk Lacrimal passage stent and lacrimal passage plug for which flange is reinforced with disk
WO2006031658A2 (en) * 2004-09-10 2006-03-23 Allergan, Inc. Therapeutic lacrimal canalicular inserts and related methods
EP1765454A2 (en) * 2004-07-02 2007-03-28 Eliot Lazar Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
JP2010213957A (en) * 2009-03-18 2010-09-30 Sugimoto Ganka Iin Lacrimal passage treatment instrument
JP2010537775A (en) * 2007-09-07 2010-12-09 キューエルティー プラグ デリバリー,インク.Qlt Plug Delivery,Inc. Lacrimal implant and related methods
JP2011200601A (en) * 2010-03-26 2011-10-13 Kaneka Corp Lacrimal duct tube
US20120215153A1 (en) * 2009-10-22 2012-08-23 Kohei Fukaya Tube device for insertion into lacrimal passage
WO2013111435A1 (en) * 2012-01-26 2013-08-01 株式会社カネカ Lacrimal duct tube
US8691265B2 (en) 2006-03-31 2014-04-08 Mati Therapeutics, Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
US8753666B2 (en) 2007-01-31 2014-06-17 Alcon Research, Ltd. Punctal plugs and methods of delivering therapeutic agents
WO2014115700A1 (en) * 2013-01-24 2014-07-31 株式会社カネカ Lacrimal duct tube
US9132088B2 (en) 2008-04-30 2015-09-15 Mati Therapeutics Inc. Composite lacrimal insert and related methods
US9216108B2 (en) 2008-02-18 2015-12-22 Mati Therapeutics Inc. Lacrimal implants and related methods
CN105377188A (en) * 2013-07-05 2016-03-02 汉阳大学校产学协力团 Nasolacrimal duct tube including lachrymal passage
US9463114B2 (en) 2004-04-15 2016-10-11 Mati Therapeutics Inc. Punctal plug with active agent
US9610271B2 (en) 2011-08-29 2017-04-04 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9949942B2 (en) 2008-05-09 2018-04-24 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
JP2018114240A (en) * 2017-01-20 2018-07-26 竜司 湯田 Catheter for lacrimation disorder treatment
US10238535B2 (en) 2009-02-23 2019-03-26 Mati Therapeutics Inc. Lacrimal implants and related methods

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988844A3 (en) * 1998-08-27 2001-07-04 MLC Limited Company Apparatus for intubation of lacrimal duct
EP0988844A2 (en) * 1998-08-27 2000-03-29 MLC Limited Company Apparatus for intubation of lacrimal duct
EP1048275A3 (en) * 1999-04-28 2001-08-22 MLC Limited Company Apparatus for intubation of lacrimal duct
US9463114B2 (en) 2004-04-15 2016-10-11 Mati Therapeutics Inc. Punctal plug with active agent
JP4510511B2 (en) * 2004-05-18 2010-07-28 有限会社エム・エル・シー A lacrimal stent and lacrimal plug with reinforced collars
JP2005328922A (en) * 2004-05-18 2005-12-02 M L C:Kk Lacrimal passage stent and lacrimal passage plug for which flange is reinforced with disk
US9180045B2 (en) 2004-07-02 2015-11-10 Mati Therapeutics Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
JP2008504938A (en) * 2004-07-02 2008-02-21 レイザー,エリオット Treatment medium delivery apparatus and method for delivering treatment medium to eyes using the delivery apparatus
EP1765454A4 (en) * 2004-07-02 2009-04-29 Qlt Plug Delivery Inc Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
EP1765454A2 (en) * 2004-07-02 2007-03-28 Eliot Lazar Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US9820884B2 (en) 2004-07-02 2017-11-21 Mati Therapeutics Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such delivery device
JP2016104206A (en) * 2004-07-02 2016-06-09 キューエルティー インコーポレイテッド Treatment medium delivery device and methods for delivery of treatment mediums to eye using such delivery device
WO2006031658A3 (en) * 2004-09-10 2006-04-13 Allergan Inc Therapeutic lacrimal canalicular inserts and related methods
WO2006031658A2 (en) * 2004-09-10 2006-03-23 Allergan, Inc. Therapeutic lacrimal canalicular inserts and related methods
US10383817B2 (en) 2006-03-31 2019-08-20 Mati Therapeutics Inc. Nasolacrimal drainage system implants for drug therapy
US8691265B2 (en) 2006-03-31 2014-04-08 Mati Therapeutics, Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
US9610194B2 (en) 2006-03-31 2017-04-04 Mati Therapeutics Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
US9849082B2 (en) 2006-03-31 2017-12-26 Mati Therapeutics Inc. Nasolacrimal drainage system implants for drug therapy
US10300014B2 (en) 2006-03-31 2019-05-28 Mati Therapeutics Inc. Nasolacrimal drainage system implants for drug therapy
US9168222B2 (en) 2006-03-31 2015-10-27 Mati Therapeutics Inc. Nasolacrimal drainage system implants for drug therapy
US8753666B2 (en) 2007-01-31 2014-06-17 Alcon Research, Ltd. Punctal plugs and methods of delivering therapeutic agents
US10434009B2 (en) 2007-09-07 2019-10-08 Mati Therapeutics Inc. Lacrimal implants and related methods
JP2010537775A (en) * 2007-09-07 2010-12-09 キューエルティー プラグ デリバリー,インク.Qlt Plug Delivery,Inc. Lacrimal implant and related methods
US9445944B2 (en) 2007-09-07 2016-09-20 Mati Therapeutics Inc. Lacrimal implants and related methods
US9216108B2 (en) 2008-02-18 2015-12-22 Mati Therapeutics Inc. Lacrimal implants and related methods
US9132088B2 (en) 2008-04-30 2015-09-15 Mati Therapeutics Inc. Composite lacrimal insert and related methods
US9764066B2 (en) 2008-04-30 2017-09-19 Mati Therapeutics Inc. Composite lacrimal insert and related methods
US9949942B2 (en) 2008-05-09 2018-04-24 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US10238535B2 (en) 2009-02-23 2019-03-26 Mati Therapeutics Inc. Lacrimal implants and related methods
JP2010213957A (en) * 2009-03-18 2010-09-30 Sugimoto Ganka Iin Lacrimal passage treatment instrument
US20120215153A1 (en) * 2009-10-22 2012-08-23 Kohei Fukaya Tube device for insertion into lacrimal passage
JP2011200601A (en) * 2010-03-26 2011-10-13 Kaneka Corp Lacrimal duct tube
US9610271B2 (en) 2011-08-29 2017-04-04 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
JPWO2013111435A1 (en) * 2012-01-26 2015-05-11 株式会社カネカ Lacrimal tube
CN104066405A (en) * 2012-01-26 2014-09-24 株式会社钟化 Lacrimal duct tube
WO2013111435A1 (en) * 2012-01-26 2013-08-01 株式会社カネカ Lacrimal duct tube
EP2949297A4 (en) * 2013-01-24 2016-07-06 Kaneka Corp Lacrimal duct tube
JPWO2014115700A1 (en) * 2013-01-24 2017-01-26 株式会社カネカ Lacrimal tube
US10058451B2 (en) 2013-01-24 2018-08-28 Kaneka Corporation Lacrimal duct tube
EP2949297A1 (en) * 2013-01-24 2015-12-02 Kaneka Corporation Lacrimal duct tube
WO2014115700A1 (en) * 2013-01-24 2014-07-31 株式会社カネカ Lacrimal duct tube
CN105377188A (en) * 2013-07-05 2016-03-02 汉阳大学校产学协力团 Nasolacrimal duct tube including lachrymal passage
JP2018114240A (en) * 2017-01-20 2018-07-26 竜司 湯田 Catheter for lacrimation disorder treatment

Similar Documents

Publication Publication Date Title
AU2009251058B2 (en) Implant and methods thereof for treatment of ocular disorders
US4886488A (en) Glaucoma drainage the lacrimal system and method
DE60016271T2 (en) drug delivery
US9101444B2 (en) Method, surgical kit and device for treating glaucoma
JP5819919B2 (en) Composite lacrimal insert and related methods
JP4677538B2 (en) Reservoir device for intraocular drug delivery
CA2463113C (en) Device for medicine delivery by intraocular iontophoresis or electroporation
US7117870B2 (en) Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
ES2237463T3 (en) Department of administration of ophthalmic drugs.
US20040015140A1 (en) Uveoscleral drainage device
EP1227792B1 (en) Ocular insert
US9445944B2 (en) Lacrimal implants and related methods
US8617094B2 (en) Fluid infusion methods for glaucoma treatment
KR100456090B1 (en) Stent device and method for treating glaucoma
US7708711B2 (en) Ocular implant with therapeutic agents and methods thereof
US20130218081A1 (en) Pharmaceutical Delivery Device and Method for Providing Ocular Treatment
JP2011092765A (en) Implant containing therapeutic agent for eye
US9463114B2 (en) Punctal plug with active agent
CN100349562C (en) Ophthalmic drug delivery device
JP4290915B2 (en) System and method for reducing intraocular pressure
CA2924955C (en) Ocular implants and methods
US5147647A (en) Ocular insert for the fornix
JP5415262B2 (en) Puncture plug for active agent delivery
CA2447802C (en) Ophthalmic drug delivery device
US3949750A (en) Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20051213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060516